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Metabolic therapies inhibit tumor 
growth in vivo and in silico
Jorgelindo da Veiga Moreira  , Minoo Hamraz , Mohammad Abolhassani , 
Laurent Schwartz , Mario Jolicœur  & Sabine Peres  
In the recent years, cancer research succeeded with sensitive detection methods, targeted drug delivery 
th century, 
Is cancer a genetic disease or a metabolic alteration? This issue has been subject to debates in the history of can-
cer1,2. The genomic hypothesis of cancer originally raised with the discovery of a proto-oncogene tyrosine-protein 
kinase (Src) responsible of cancer in chicken. J. Michael Bishop and Harold E. Varmus, two Nobel Prize winners 
(1989) discovered in 1979 that mutations in src gene in normal chickens can lead to cancer3. Then, the genomic 
area of cancer reached its peak with the complet sequencing of the human genome by the International Human 
Genome Sequencing Consortium in 20014. This has opened new markets for the pharmaceutical industry while 
defining new approaches in cancer therapy. For instance synthetic drugs such as Cisplatin and 5-Fluorouracil 
where introduced and are now part of the chemotherapeutic regimen. However, the limited success of these 
chemotherapeutic agents opened avenues for new strategies. New thoughts wave has emerged with a disrup-
tive synthetic review aiming at redefining “The hallmarks of Cancer” and the common rules that govern the 
reprogramming of normal cells into malignant cancers5. Hanahan and Weinberg described common molecular 
machinery involved in regulating cell proliferation, differentiation and death. Indeed, dysfunctions on the inter-
nal “machine” or on its environment lead to the same deleterious phenotype: “sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, replicative immortality, sustained angiogenesis, and activating 
invasion and metastasis”. More recently, the same authors proposed an updated version of the previous review 
where they added “two emerging hallmarks”, including “reprogramming of energy metabolism and evading 
immune destruction6”. These new concepts have been the subject of numerous studies these last years7, including 
those from our research group8–11.
To the question of whether cancer is a genetic disease or a metabolic alteration, hypothesis enabled explaining 
how cancer cells’ metabolic reprogramming confer them an advantage from normal cells12–14. Our studies among 
others contributed rehabiliting past studies from the german Nobel Prize winner, Otto Warburg, who introduced 
the idea of metabolic alteration in cancer cells15. In his seminal article, Warburg (1956) presented the concepts of 
“uncoupling of respiration” and “aerobic glycolysis” occurring in cancer cells, to explain that cancer cells rely on 
the cytoplasmic fermentation of glucose to lactic acid for energy (ATP) synthesis rather than the oxidative phos-
phorylation16. Otto Warburg explained this observation as a phenotypic expression of deleterious mitochondria. 
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This characteristic of cancerous cells, labeled as the Warburg effect, has been the subject of extensive investiga-
tions the past years17. The Warburg effect confers a metabolic advantage to the cancerous tissue compared to 
normal somatic cells. This has been described as a consequence of the hybridic aspect of cancer cells metabolism 
where anabolism and catabolism occur simultaneously14. Carbon substrates are catabolized and intermediate 
compounds used as primary source for building blocks synthesis (lipids, proteins and nucleic acids), essential 
for cell growth18–20. This hybrid metabolism explains why targeting one pathway with a chemoterapeutic agent is 
barely enough to stop tumor growth. Indeed, metabolic and epigenetic reprogramming of cancer cells confer a 
metabolic plasticity in their central carbon metabolism (CCM), which could explain their acquired resistance to 
current chemotherapies.
To this end, an interesting approach would be to target the CCM using metabolic drugs known to inhibit 
specific enzymes. Among enzymes of the CCM, both pyruvate dehydrogenase (PDH) and ATP citrate lyase 
(ACL) play key role in metabolic reprogramming of cancer cells18. PDH enzymatic complex converts pyruvate to 
acetyl-CoA and fuels the tricarboxylic acid cycle in normal cells. In cancer cells, PDH has been shown to be inhib-
ited whereas ACL is overexpressed. ATP citrate lyase converts cytoplasmic citrate to oxaloacetate and acetyl-CoA, 
a precursor for lipid synthesis. Other key enzymes playing pivotal role on cancer metabolism are lactate dehydro-
genase (LDH) and enzymes involved on the electron transfer chain (ETC) reactions. Indeed, metabolic therapies 
targeting these enzymatic reactions involved in carbon resources fermentation could limit their uptake by the 
tumor in order to vanish the Warburg phenotype.
We used Alpha Lipoic Acid (ALA) and Hydroxycitrate (HCA), two old drugs from the pharmacopoeia tar-
geting PDH and ACL, respectively. Interestingly, we managed to show that combination of ALA and HCA deeply 
inhibits cultures of three cancer cell lines (MBT-2 bladder carcinoma, B16-F10 melanoma and LL/2 lung carci-
noma)21. These results agree with that from Hatzivassiliou and colleagues who reported the inhibition of cancer 
cells growth when using specific silencing RNA (SiRNA) to vanish ACL protein expression22. Similarly, a study 
from Bonnet and colleagues (2006) demonstrated the efficacy of a small molecule, Dichloroacetate, in restor-
ing PDH activity in cancer cells23. Taken together, these experimental results show the potential of targeting 
enzymes involved in programming the Warburg effect. These therapeutic approaches show a similar efficacy 
as for conventional therapies but without any side effects. Furthermore, we have also investigated the efficacy 
of our drug combination, namely METABLOC (ALA and HCA), used in synergy with standard chemotherapy 
drugs such as Cisplatin or Methotrexane24. We reported an enhanced delay in tumor growth when Cisplatin and 
Methotrexane are applied in combination with METABLOC. A standardized screening method allow identifying 
the best drug combinations to asses their effects on cancer cells metabolism and tumor growth25. A pre-clinical 
investigation thus consisted to further evaluate the effect of METABLOC combined to new drugs (Metformin 
and Diclofenac) on the growth of transplanted LL/2 Lewis lung carcinoma into mice. The choice of these two 
drugs is based on their reported positive effect at slowing tumor growth. Metformin is an old drug commonly 
used in type II diabeties [Diabetes Prevention Program Research Group]. Emerging studies are showing the 
positive effect of using Metformin in cancer therapy26–28. Since Metformin is used as an hypoglycemic drug in 
type II diabeties, it slows down insulin secretion and cell proliferation by decoupling mitochondrial respiration 
throughout the ETC. Interestingly, retrospective epidemiological studies have shown that diabetic patients with 
long-term Metformin treatment have a reduced risk of developing cancer26,29. Moreover, another pre-clinical 
study showed an anti-proliferative effect of Metformin on tumor xenograft in mice30. Diclofenac is also an old 
drug currently used as an anti-inflammatory agent. Recent studies mentioned the potential use of Diclofenac in 
cancer treatment31–33. For instance, Gottfried et al. (2013) showed that Diclofenac impairs the Warburg effect by 
targeting glucose transport into cancer cells and inhibiting lactate dehydrogenase (LDH) and monocarboxylate 
Transporter 1 (MCT1). This results in decreased glucose uptake and lactate secretion.
In this work, we injected xenograft of LL/2 Lewis lung carcinoma cells into the peritoneal cavity of mice and 
we tested the effect of different combinations of drugs on the tumor volume evolution. Results show a decrease 
in LL/2 tumor volume when METABLOC is administrated in combination with Diclofenac and Metformin. 
The METABLOC effect is enhanced when Metformin is used at high-dose. Results are compared to the case 
of administration of a classic chemotherapeutic agent (Cisplatin), as a positive control. We also set up a kinetic 
metabolic model of tumor growth in order to characterize the effect of metabolic therapies on tumor metabolism. 
The model was not only able to simulate tumor growth in accordance with experimental data, but also allowed 
to simulate inhibition of growth after application of the metabolic therapy. This approach to kinetic modeling of 
tumor growth opens avenues to the identification of new metabolic targets.
Results
We first analyzed the effect 
of exposing groups of C57BL/6 mice (n = 10) bearing the LL/2 Lewis lung tumor xenograft to chronic low and 
high-dose of Metformin and Diclofenac. As control, we also designed groups for chronic injection of Phosphate 
Buffer Saline (PBS), Cisplatin (chemoterapeutic drug) and METABLOC (calcium hydroxycitrate + lipoic acid). 
Results are reported in Fig. 1. Mice group treated with PBS, as negative control, reaches a tumor volume of 
4000 mm3, whereas the group treated with Cisplatin (positive control) have half of the tumor volume at day 59 
(Fig. 1a,b). We also applied chronic dose of METABLOC, already used in our previous studies. This combination 
of calcium citrate (HCA) and lipoic acid (ALA) does reduce tumor growth, as reported in our previous works 
(Fig. 1c). High-dose of Metformin and Diclofenac slightly delay tumor growth from day 10 to day 59 after cell 
inoculation (Fig. 1e,g). Low-dose metformin also delays tumor growth but not low-dose diclofenac (Fig. 1d,f). 
Metformin shows a dose-response effect on tumor volume (3500 mm3 for low-dose and 3300 mm3 for high-
dose). This is not the case of Diclofenac-treated group where the high-dose Diclofenac slightly reduces the tumor 
volume (mean value = 3300 mm3) but the low-dose group is similar to PBS at day 59 (Fig. 1). Experiments were 
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stopped at day 59 since PBS group reaches a lethal tumor volume. Then another group were fed with METABLOC 
and Metformin or Diclofenac.
METABLOC 
combination with high-dose Metformin and Diclofenac significantly delays LL/2 carcinoma progression in mice com-
pared to PBS or METABLOC treatment (Fig. 2b,c). METABLOC with low-dose Metformin also have a positive effect 
whereas its combination with low-dose diclofenac has poor effect (Fig. 2d). Among these curves, only METABLOC and 
high-dose Metformin treated group shows a regression in tumor volume (Fig. 2b). The mean tumor volume is signifi-
cantly decreased from day 45 to day 59 in the case of METABLOC + Metformin (high-dose) combination (p < 0.005). 
The tumor has a better response to our combination compared to Cisplatin treatment (p < 0.001). High-dose 
Metformin clearly enhances our previous METABLOC combination (Hydroxycitrate + Lipoic acid).
We went further 
in our investigation and treated a group of mice (n = 10) with full combination of METABLOC + Metformin 
(low and high-dose) + Diclofenac. Addition of high-dose Diclofenac to METABLOC + high-dose Metformin 
improves the tumor response to treatment (Fig. 2e). Tumor volume starts regressing at day 45 in METABLOCS 
(METABLOC + Metformin (high-dose) + Diclofenac (high-dose)) treated group whereas that regres-
sion is observed at day 52 for METABLOC + Metformin (high-dose) (Fig. 2b). Combination with low-dose 
Metformin is less pronounced. METABLOCS significantly decreases tumor growth at day 59 compared to 
METABLOC + high-dose Metformin (p < 0.001) (Fig. 2b). Compared to Cisplatin-treatment, METABLOC 
has less effect but tumor cell sensitivity increases when the last is combined with metformin and then with 
Metformin + Diclofenac. Combinations of these old and low-cost drugs are two-times more efficient than the 
classic chemotherapeutic agent. Our new finding is that a combination of METABLOC (Hydroxycitrate + Lipoic 
acid) and high-dose Metformin strongly inhibits growth of tumor xenograft inoculated to a group of mice 
(n = 10).
In silico A kinetic metabolic model (see the 
metabolic network in Fig. 3 and the system of differential equations in methods) has been set up from previ-
ous models describing the simulation of Chinese Hamster Ovary cells (CHO) growth on different media for 
the production of monoclonal antibodies34. Here, our model is first used to simulate the growth of a tumor 
xenograft implanted to a group of mice. Then, the model was used to simulate the impact of in silico metabolic 
therapy - METABLOC - Metformin - Diclofenac on tumor growth. This model is not only useful for simulating 
Figure 1. Xenograft tumor evolution in mice under metabolic therapies. Treatments started at day twelve 
after tumor inoculation in mice. The thin curves represent tumor volumes for each single mouse. The red bold 
curves are the mean values of all the thin curves. (a) Phosphate-buffered saline (PBS) is used as a control. (b) 
The chemotherapeutic agent, Cisplatin, slows down tumor growth. (c) Tumor growth is slightly reduced under 
METABLOC therapy. (d–g) Low-dose and high-dose Metformin and Diclofenac have no significant effects on 
tumor evolution.
4SCIENTIFIC REPORTS |          (2019) 9:3153  | 
www.nature.com/scientificreportswww.nature.com/scientificreports/
experimentally obtained tumor growth, but it also allowed us to characterize the metabolic phenotypes the tumor 
developing in mice with time.
The model simulates adequately tumor xenograft growth in mice for the most efficient treatment strat-
egy (Fig. 4a). The predicted tumor volume is within the standard deviations of experimental tumor volume. 
The model predicts a tumor volume evolution from 154 mm3 to 3900 mm3, in line with the experimental data 
(154 ± 16 to 4076 ± 297 mm3). It is important to note that model predictions are only based on total tumor cell 
volume and blood network of capillaries. Results thus confirming model ability to describe tumor growth. For the 
model integrating metabolic therapy, the therapeutic molecules are supplied within the blood inlet flux (F) feed-
ing the capillaries blood volume (i.e. tumor cells microenvironment). These molecules are known to specifically 
target specific enzymatic pathways; with the known effects on cell metabolism that are explicitly described in the 
model. Model simulations describe the inhibition of tumor growth by metabolic therapy (METABLOC + Metf
ormin + Diclofenac) Fig. 4b. Both experimental and predicted data of tumor evolution show a reduced growth 
phase from t0 (10 days after tumor inoculation) and reach a plateau at day 35. Model simulations show a growth 
plateau at around 873 mm3 as for the experimental data (873 ± 70 mm3). However, the model does not simulate 
the decrease in tumor volume. This is probably due to the occurence of apoptosis in the tumor, a phenomenon 
that is not described in the model.
In a recent 
work35, we reported concentrations of key metabolites involved in energy management throughout the central 
carbon metabolism. Concentrations of adenosine triphosphate (ATP), nicotinamide adenine dinucleotide (NAD), 
and nicotinamide adenine dinucleotide phosphate (NADP) have been measured in normal and cancer cells, 
extracted from fresh human colon tissues. Our results showed high NAD+-to-NADH and NADP+-to-NADPH 
redox ratios in cancer cell populations compared to normal proliferating cells. Interestingly enough, our model 
also predicts the high throughput aerobic glycolysis, commonly known as the Warburg effect, observed in cancer 
cells (Fig. 5(a,c)). Consumption of glucose by the tumor cells is linear, until reaching limitation level at the end 
of the 25th day and totally consumed 59 days after incubation. This accelerated glycolysis results in a massive 
Figure 2. Tumor evolution under metabolic therapy combinations. The thin curves represent tumor volumes 
for each single mouse. The red bold curves are the mean values of all the thin curves. (a) METABLOC + low-
dose Metformin slows down tumor growth. (b) METABLOC + high-dose Metformin significantly reduces 
tumor evolution and inhibits tumor growth at day 50 from cell inoculation. (c,d) METABLOC + low-dose 
and high-dose Diclonenac has no significant effect on tumor growth inhibition. (e) METABLOC + high-dose 
Metformin and Diclofenac drastically inhibits tumor growth and reverses the tumor curve.
5SCIENTIFIC REPORTS |          (2019) 9:3153  | 
www.nature.com/scientificreportswww.nature.com/scientificreports/
release and accumulation of lactate in the blood stream. NAD+-to-NADH is the catabolic marker of that aer-
obic glycolysis proposed by Warburg in his seminal article16. Therefore, an important NAD+-to-NADH ratio 
allows the maintenance of the glycolytic potential of cancer cells. Combining METABLOC and high-dose of 
Metformin and Diclonenac considerably reduces glucose consumption by tumor cells. This phenomenon thus 
Figure 3. The metabolic network. The core metabolism of cancer cells integrates glycolysis, the pentose 
phosphate pathway, the citric acid cycle, lipogenesis and amino acids metabolism. Biomass synthesis is 
described as the incorporation of amino acids, intermediate metabolites and palmitic acid. The metabolic 
therapy includes Diclofenac as hexokinase and lactate dehydrogenase inhibitor; alpha-Lipoic acid (ALA) 
as pyruvate dehydrogenase activator; Hydroxycitrate (HCA) as ATP citrate lyase inhibitor; Metformin as 
ATP synthase inhibitor and NAD leakage activator. Notations: ACCOA: Acetyl-CoenzymeA, ACCOA: 
Acetyl-CoenzymeA, ACL: ATP-citrate lyase, ADP: Adenosine diphosphate, AK: Adenylate kinase, AKG: 
α-ketoglutarate, ALA: Extracellular alanine, AMP: Adenosine monophosphate, ARG: Extracellular arginine, 
ASN: Asparaginase, ASP: Extracellular aspartate, ATP: Adenosine triphosphate, CIT: Citrate, CO2: Carbone 
dioxide, DICLO: Extracellular diclofenac, EGLC: Extracellular glucose, EGLN: Extracellular glutamine, EGLU: 
Extracellular glutamate, F6P: Fructose-6- Phosphate, FADH2: Flavine adenine dinucleotide, FUM: fumarate, 
G6P: Glucose-6-phosphate, GAP: Glyceraldehyde 3-phosphate, concentration, GlnT: Glutamine synthetase, 
GLU: Glutamate, GLY: Extracellular Glycine, H2O: Hydrogen dioxide, HCIT: Extracellular hydroxicitrate, 
HIS: Extracellular histidine, HISARGTA: Histidine/arginine transamination, ILE: Extracellular isoleucine, LA: 
Extracellular lipoic acid, LAC: Extracellular lactate, LEU: Extracellular leucine, LYS: Extracellular lysine, MAL: 
Malate, ME: Malic enzyme, Metformin: Extracellular metformin, NAD: Nicotinamide adenine dinucleotide 
(Oxidized), NADH: Nicotinamide adenine dinucleotide (reduced), NADP: nictoniamide adenine dinucleottide 
phosphate, NADPH: nictoniamide adenine dinucleotide phosphate (reduced), NH4: Extracellular ammonia, 
OXA: Oxaloacetate, PALM: Palmitate, PEP: Phosphoenolpyruvate, Pi: inorganic phosphate, PK: Pyruvate 
kinase, PPRibP: Nucleotide synthesis, PYR: Pyruvate, R5P: Ribulose-5-phosphate, SER: Extracellular serine, 
SUC: succinate, SUCCOA: Succinyl coenzyme A, THR: Extracellular threonine, TYR: Extracellular tyrosine, 
VAL: Extracellular valine.
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Figure 4. Predictions of the tumor growth in control and underin silico metabolic therapy. (a) The kinetic 
model of tumor metabolism simulates tumor volume in line with the experimental data. (b) Under metabolic 
therapies (METABLOC combined with diclofenac and high dose of Metformin), the model predicts tumor 
inhibition and its volume regression, as determined experimentally.
Figure 5. Simulated blood metabolites (glucose and lactate) and simulated redox ratio (NAD+/NADH) in 
tumor (a) and tumor treated with metabolic drugs (b). Simulated fluxes of lactate dehydrogenase (VLDH) and 
respiration (Vresp) in tumor (c) and tumor treated with metabolic drugs (d). (a) Lactic acid is first eliminated 
by the blood flow and then accumulates with tumor growth. NAD+/NADH ratio decreases upon glucose 
exhaustion. (b) Under metabolic therapy glucose uptake slows down, as well as lactic acid secretion. NAD+/
NADH ratio decreases with tumor growth. (c) The high value of VLDH and the decrease of the respiration flux 
are markers of the Warburg effect in the tumor. (d) The negative flux of VLDH which corresponds to lactate 
uptake and the increase of the respiration flux both translate a reverse Warburg effect.
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results in decreased lactate secretion and accumulation (Fig. 5(b,d)). NAD+-to-NADH redox ratio is low and 
decreases with metabolic therapies. These observations are both signatures of a reduced glycolytic flux or the 
reverse Warburg effect.
Metabolic therapies have been used to study tumor xenograph growth in mice. We experimentally showed that 
the combination of METABLOC, high-dose Metformin and Diclofenac inhibits the tumor growth. We proposed 
a dynamic metabolic model of the tumor which simulates the effects of the metabolic therapies on tumor evolu-
tion and tumor cell metabolism. This model also predicts tumor regression, a lower glycolytic flux and lactic acid 
secretion upon metabolic treatments. Intracellular NAD+/NADH redox ratio is low and decreases, as a conse-
quence of reduced glycolytic flux. Indeed, the oxidative phosphorylation may be rewired from the fermentation 
pathway, favoring mitochondrial respiration and inversed Warburg effect. Our model supports our experimental 
results and it can also be use to test new combination of metabolic treatments. These results pave the way for new 
strategies in metabolic therapy and in silico metabolic drug design.
Methods
The LLC/1 cell-line ATCC® CRL-1642 (LGC Standards, Molsheim-France) cultivated in the 
medium DMEM Glutamax I (Invitrogen-Gibco) with 10% of FBS (Eurobio) and 1/10000 IU of Penicillin/
Streptomycin (Sigma Aldrich P4333) were injected into the peritoneal cavity of mice at 5 million cells per mouse 
in a 150 shot and within 12 days of incubation, when tumors reached 130 mm3, mice were randomized and the 
treatments were started.
Lipoic acid (Sigma Aldrich T1395), calcium hydroxycitrate(IWDO) and cisplatin 
(Sigma Aldrich 479306) were dissolved in PBS and injected intraperitoneally (i.p.) two times per day (2X/D) 
for lipoic acid and calcium hydroxycitrate, 1X/2D for cisplatin at 10 mg/kg, 250 mg/kg and 1 mg/kg, respec-
tively. Drops of ethanol were added to completely dissolve lipoic acid in PBS solution. Diclofenac sodium 
(Sigma-Aldrich 93484) at 3 mg/kg and 30 mg/kg adjusted in 25 μL/mL (LOW) and 250 μL/mL (HIGH) 
of drinking water were administered orally (Per Os). A mouse drinks about 3 mL water per day. Metformin 
(Sigma-Aldrich 1396309) at 2.5 mg/kg, 12.5 mg/kg and 25 mg/kg adjusted in 20 μ/mL (LOW), 100 μL/mL 
(MEDIUM) and 200 μL/mL (HIGH) of drinking water were also administered orally.
Mice were divided in a weight-normalized manner into the groups of 10 animals per 
group. Forty eight groups of 6–8 weeks old inbred male C57BL/6 mice (mean weight: 21.15 ± 1.11 g) were 
obtained from Pasteur Institute, Iran. They were housed five to a cage with access to autoclaved mouse chow 
and water ad libitum. They were kept in a room under controlled temperature (22 °C), humidity (55%) and light 
(lights on 7 h00 am–7 h00 pm). All animals received human care in compliance with the Guide for the Care and 
Use of Laboratory Animals [DHEW Publication No. (NIH) 85–23, from 1985 with all next updates, Office of 
Science and Health Reports, DRR/NIH, Bethesda, MD 20205]. The experimental protocols were approved by the 
company Nosco Pharmaceuticals.
The metabolic network presented here and displayed in Fig. 3 has been modi-
fied from previous models of Chinese Hamster Ovary cells (CHO) and mouse myeloid derived suppressor cells 
(MD-SCs)34,36–39. It includes 35 enzymatic reactions describing the fate of 52 metabolites. We distinguished two 
compartments: external (i.e. blood microenvironment of tumor cells) and intracellular cell metabolites, with the 
cell as a unique compartment. The network integrates pathways of the central carbon metabolism (CCM) such as 
glycolysis, the pentose phosphate pathway, the tricarboxylic acid cycle, lipogenesis, the oxidative phosphorylation 
and pathways of amino acid metabolism. In this CCM, glucose and amino acids are the main sources of carbon 
and nitrogen for cell proliferation and biomass synthesis. For further details see34.
The concept of minimal cut set has been introduced 
to determine the minimal set of reactions whose deletion completely blocks a target40. In our metabolic net-
work, there are 1058 minimal cut sets which prevent the tumor growth (X). They have been calculated with 
CellNetAnalyzer41,42 and we have selected the shortest. Twenty of them have their size lower than two and only 
6 are of size one: VHK, VG6PDH, VCS, VACL, VPALM, Vgrowth. As our therapy is not a genetic modification, 
the inhibition of one of them will not totally prevent the tumor growth. This structural analysis shows that the 
diclofenac which inhibits the hexokinase (VHK), and the hydroxycitrate which inhibits the ATP citrate lyase 
(VACL), should have a negative impact on the tumor growth.
The tumor volume includes cancer cells and the network of cap-
illaries (Fig. 6). The model was established on the basis of mass balances on metabolites and tumor cells con-
centration. The tumor cells are continuously perfused from a network of capillary of total volume Vb, which is 
considered as a perfectly mixed stirred-tank reactor (CSTR). The blood composition within the tumor volume 
was thus considered homogeneous. In a perfusion system the cells are retained within the vessel.
The tumor is continuously fed from the network of capillaries, with a global blood flow rate (F) of composition 
C0 at tumor inlet. For simplification purposes, the variation of the blood flow with tumor growth was neglected. 
Here, C and C0 are the vectors of tumor blood concentrations and blood concentrations in metabolites at tumor 
inlet, respectively (in mM), and m is the vector of concentrations of tumor cells intracellular metabolites (in mM). 
Sc and Sm are the stoichiometric matrices of the reactions involving the extracellular and intracellular metabo-
lites, respectively. The r term is the specific rates vector (in mM/h in cells and mmol/106 cells/h in capillaries) of 
each reaction in the metabolic network, whilst μ and μblood are the cells and capillaries specific growth or volume 
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increase rates (h−1), respectively. X is the total tumor cells volume (in 106 cells/ml) and εm is the fraction of intra-
cellular metabolites that are integrated into the cells matter. The dynamical system is written as follow and is 
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Parameters value where first taken from previous works on CHO cells34,36, when 
not available for cancer or human cells in the literature or databanks. Then, we used nonlinear optimization func-
tion, fmincon (MatWorks®), to optimize sensitive parameters which are Fin, Fout and the specific growth rate of 






























,  is the nth experimental data at the tth experimental time, Yn,t(p) the simulated output with “p” a vector 
of the three sensitive parameters and “σ” the standard deviation of the experimental measurements.
 1. Seyfried, T. N. & Shelton, L. M. Cancer as a metabolic disease. Nutr. & Metab. 7, 7, https://doi.org/10.1186/1743-7075-7-7 (2010).
 2. Gatenby, R. A. Is the Genetic Paradigm of Cancer Complete? Radiology 284, 1–3, https://doi.org/10.1148/radiol.2017171004 (2017).
 3. Oppermann, H., Levinson, A. D., Varmus, H. E., Levintow, L. & Bishop, J. M. Uninfected vertebrate cells contain a protein that is 
closely related to the product of the avian sarcoma virus transforming gene (src). Proc. Natl. Acad. Sci. United States Am. 76, 
1804–1808 (1979).
 4. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921, https://doi.org/10.1038/35057062 
(2001).
 5. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
 6. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674, https://doi.org/10.1016/j.
cell.2011.02.013 (2011).
 7. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet (London, England) 357, 539–545, https://doi.
org/10.1016/S0140-6736 (2001).
 8. Abolhassani, M. et al. Hyperosmolarity causes inflammation through the methylation of protein phosphatase 2a. Inflamm. Res. Off. 
J. Eur. Histamine Res. Soc. et al. 57, 419–429, https://doi.org/10.1007/s00011-007-7213-0 (2008).
 9. Abolhassani, M., Guais, A., Chaumet-Riffaud, P., Sasco, A. J. & Schwartz, L. Carbon dioxide inhalation causes pulmonary 
inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L657–665, https://doi.org/10.1152/ajplung.90460.2008 (2009).
Figure 6. Tumor microenvironment assimilated to a perfusion reactor.
9SCIENTIFIC REPORTS |          (2019) 9:3153  | 
www.nature.com/scientificreportswww.nature.com/scientificreports/
 10. Schwartz, L. et al. Hyperosmotic stress contributes to mouse colonic inflammation through the methylation of protein phosphatase 
2a. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G934–941, https://doi.org/10.1152/ajpgi.90296.2008 (2008).
 11. Schwartz, L., Guais, A., Pooya, M. & Abolhassani, M. Is inflammation a consequence of extracellular hyperosmolarity? J. Inflamm. 
(London, England) 6, 21, https://doi.org/10.1186/1476-9255-6-21 (2009).
 12. Israël, M. & Schwartz, L. The metabolic advantage of tumor cells. Mol. Cancer 10, 70, https://doi.org/10.1186/1476-4598-10-70 
(2011).
 13. Israël, M. A possible primary cause of cancer: deficient cellular interactions in endocrine pancreas. Mol. Cancer 11, 63, https://doi.
org/10.1186/1476-4598-11-63 (2012).
 14. Israel, M. Comment on cancer metabolism and on the role of the endocrine pancreas. J. Clin. Medicine Res. 6, 490–491, https://doi.
org/10.14740/jocmr1912w (2014).
 15. Warburg, O., Wind, F. & Negelein, E. The Metabolism Of Tumors In The Body. The J. Gen. Physiol. 8, 519–530 (1927).
 16. Warburg, O. On the origin of cancer cells. Sci. (New York, N.Y.) 123, 309–314 (1956).
 17. Gatenby, R. A. & Frieden, B. R. Information dynamics in carcinogenesis and tumor growth. Mutat. Res. 568, 259–273, https://doi.
org/10.1016/j.mrfmmm.2004.04.018 (2004).
 18. Deberardinis, R. J., Sayed, N., Ditsworth, D. & Thompson, C. B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. 
Genet. & Dev. 18, 54–61, https://doi.org/10.1016/j.gde.2008.02.003 (2008).
 19. Kroemer, G. & Pouyssegur, J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13, 472–482, https://doi.org/10.1016/j.
ccr.2008.05.005 (2008).
 20. da Veiga Moreira, J. et al. Cell cycle progression is regulated by intertwined redox oscillators. Theor. Biol. Med. Model. 12, 10, https://
doi.org/10.1186/s12976-015-0005-2 (2015).
 21. Schwartz, L. et al. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: 
preliminary results. Oncol. Reports 23, 1407–1416 (2010).
 22. Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311–321, https://doi.org/10.1016/j.
ccr.2005.09.008 (2005).
 23. Bonnet, S. et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and 
triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 
113, 2630–2641, https://doi.org/10.1161/CIRCULATIONAHA.105.609008 (2006).
 24. Guais, A. et al. Adding a combination of hydroxycitrate and lipoic acid (METABLOCTM) to chemotherapy improves effectiveness 
against tumor development: experimental results and case report. Investig. New Drugs 30, 200–211, https://doi.org/10.1007/s10637-
010-9552-x (2012).
 25. Abolhassani, M. et al. Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly 
effective drug combination in mice. Investig. New Drugs 30, 1331–1342, https://doi.org/10.1007/s10637-011-9692-7 (2012).
 26. Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. & Morris, A. D. Metformin and reduced risk of cancer in diabetic 
patients. BMJ 330, 1304–1305, https://doi.org/10.1136/bmj.38415.708634.F7 (2005).
 27. Sahra, I. B., Marchand-Brustel, Y. L., Tanti, J.-F. & Bost, F. Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic 
Drug? Mol. Cancer Ther. 9, 1092–1099, https://doi.org/10.1158/1535-7163.MCT-09-1186 (2010).
 28. Loubiere, C., Dirat, B., Tanti, J. & Bost, F. Metformine et cancer: passé, présent, avenir. Obesite 3, 205–213 (2014).
 29. Libby, G. et al. New Users of Metformin Are at Low Risk of Incident Cancer A cohort study among people with type 2 diabetes. 
Diabetes Care 32, 1620–1625, https://doi.org/10.2337/dc08-2175 (2009).
 30. Krisztina, K., Aune, M., James, S.-S., Guido, E. & Enrique, R. Metformin Inhibits the Growth of Human Pancreatic Cancer 
Xenografts. Pancreas 42, 781–785, https://doi.org/10.1097/MPA.0b013e31827aec40 (2013).
 31. Gottfried, E. et al. New aspects of an old drug–diclofenac targets MYC and glucose metabolism in tumor cells. PloS One 8, e66987, 
https://doi.org/10.1371/journal.pone.0066987 (2013).
 32. Mayorek, N., Naftali-Shani, N. & Grunewald, M. Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by 
modulation of VEGF levels and arginase activity. PloS One 5, e12715, https://doi.org/10.1371/journal.pone.0012715 (2010).
 33. Al-Nimer, M. S., Hameed, H. G. & Mahmood, M. M. Antiproliferative effects of aspirin and diclofenac against the growth of cancer 
and fibroblast cells: In vitro comparative study. Saudi. Pharm. J. 23, 483–486, https://doi.org/10.1016/j.jsps.2015.01.002 (2015).
 34. Robitaille, J., Chen, J. & Jolicoeur, M. A Single Dynamic Metabolic Model Can Describe mAb Producing CHO Cell Batch and Fed-
Batch Cultures on Different Culture Media. PloS One 10, e0136815, https://doi.org/10.1371/journal.pone.0136815 (2015).
 35. da Veiga Moreira, J. et al. The Redox Status of Cancer Cells Supports Mechanisms behind the Warburg Effect. Metabolites 6, https://
doi.org/10.3390/metabo6040033 (2016).
 36. Ghorbaniaghdam, A., Henry, O. & Jolicoeur, M. A kinetic-metabolic model based on cell energetic state: study of CHO cell behavior 
under Na-butyrate stimulation. Bioprocess Biosyst. Eng. 36, 469–487, https://doi.org/10.1007/s00449-012-0804-3 (2013).
 37. Ghorbaniaghdam, A., Chen, J., Henry, O. & Jolicoeur, M. Analyzing clonal variation of monoclonal antibody-producing CHO cell 
lines using an in silico metabolomic platform. PloS One 9, e90832, https://doi.org/10.1371/journal.pone.0090832 (2014).
 38. Ghorbaniaghdam, A., Henry, O. & Jolicoeur, M. An in-silico study of the regulation of CHO cells glycolysis. J. Theor. Biol. 357, 
112–122, https://doi.org/10.1016/j.jtbi.2014.04.035 (2014).
 39. Goffaux, G., Hammami, I. & Jolicoeur, M. A Dynamic Metabolic Flux Analysis of Myeloid-Derived Suppressor Cells Confirms 
Immunosuppression-Related Metabolic Plasticity. Sci. Reports 7, 9850, https://doi.org/10.1038/s41598-017-10464-1 (2017).
 40. Klamt, S. & Gilles, E. Minimal cut sets in biochemical reaction networks. Bioinformatics 20, 226–234 (2004).
 41. Klamt, S., Saez-Rodriguez, J. & Gilles, E. Structural and functional analysis of cellular networks with cellnetanalyzer. BMC Syst. Biol. 
1, 2, https://doi.org/10.1186/1752-0509-1-2 (2007).
 42. von Kamp, A., Thiele, S., Hädicke, O. & Klamt, S. Use of cellnetanalyzer in biotechnology and metabolic engineering. J. Biotechnol. 
261, 221–228, https://doi.org/10.1016/j.jbiotec.2017.05.001 Bioinformatics Solutions for Big Data Analysis in Life Sciences 
presented by the German Network for Bioinformatics Infrastructure (2017).
We especially thank Jean-Marc Steyaert and Marcel Levy Nogueira for interesting discussions and suggestions for 
the experimental part of this article.
J.D.M., M.J., L.S. and S.P. conceived the study. J.D.M. implemented the calculations. J.D.M., M.J., L.S. and 
S.P. analyzed and discussed the results. J.D.M., M.J. and S.P. wrote the manuscript. M.H. and M.A. made the 
experiments.
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-39109-1.
Competing Interests: The authors declare no competing interests.
1 0SCIENTIFIC REPORTS |          (2019) 9:3153  | 
www.nature.com/scientificreportswww.nature.com/scientificreports/
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
